Loading
NASDAQHealthcareBiotechnology
Latest quote
$301.81
+$6.81 · +2.31%
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Previous close
$301.81
+$6.81 · +2.31%
Regular session · ET · Market data may be delayed.
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Day range
Current $301.81
52-week range
Current $301.81
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
74
Undervalued
Sentiment
57
Mixed
Risk
27
Moderate Risk
Momentum
65
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Day range
Current $301.81
52-week range
Current $301.81
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 268.09M USD | 167.13M USD | 131.31M USD | 196.25M USD | 241.54M USD |
| Cost of goods sold | 6.59M USD | 11.07M USD | 35.05M USD | 52.83M USD | 62.18M USD |
| Gross profit | 261.5M USD | 156.06M USD | 96.27M USD | 143.42M USD | 179.37M USD |
| Research and development | 81.18M USD | 21.43M USD | 24.54M USD | 36.08M USD | 32.11M USD |
| Selling, general, and administrative | 92.45M USD | 78.65M USD | 52.79M USD | 70.06M USD | 46.79M USD |
| Operating expenses | 214.3M USD | 178.67M USD | 84.32M USD | 140.38M USD | 75.52M USD |
| Interest income | 13.66M USD | 8.06M USD | 7.71M USD | 2.05M USD | 886K USD |
| Interest expense | 4.72M USD | 3.04M USD | 656K USD | 1.8M USD | 19.62M USD |
| Depreciation and amortization | 33.78M USD | 35.24M USD | 36.52M USD | 43.39M USD | 50.95M USD |
| Operating income | 47.2M USD | −22.61M USD | 11.94M USD | 3.04M USD | 103.85M USD |
| Net income | 124.45M USD | −4.03M USD | 52.15M USD | −33.36M USD | 57.14M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$339.43
12.46% upsideCash distributions grouped by calendar year; partial years are marked.
$0.456
2010 complete year-95.1% since 2007
$9.3575
2,007
$0.456
2,010
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 2, 2010 | $0.1218Special | Jun 28, 2010 | — |
Dividend | Apr 3, 2007 | $2.50Special | Apr 5, 2007 | Apr 19, 2007 |
Ex-dividend Jul 2, 2010
$0.1218
Special
Record Jun 28, 2010
Ex-dividend Apr 3, 2007
$2.50
Special
Record Apr 5, 2007 · Payment Apr 19, 2007
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR351.19M0.34%103.19B USD0.06%$137.55+0.17%
Vanguard Morningstar Total Stock Market ETFVTI172.5M0.01%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM155.49M0.20%78.74B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB124.45M0.07%185.3B USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR79.04M0.12%68.2B USD0.05%$234.43+0.22%
Vanguard Extended Market ETFVXF66.17M0.07%95.4B USD0.05%$235+0.80%
Invesco S&P SmallCap Momentum ETFXSMO57.98M2.02%2.87B USD0.35%$81.75+0.57%
iShares Russell 2000 Growth ETFIWO54.72M0.40%13.92B USD0.24%$356.78+0.94%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFInvesco S&P SmallCap Momentum ETFXSMOiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
